News
11-10-2010, 05:50 AM
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.
More... (http://www.news-medical.net/news/20101110/Data-from-AVEOs-tivozanib-FOLFOX6-combination-Phase-1b-trial-presented-at-22nd-EORTC-NCI-AACR.aspx)
More... (http://www.news-medical.net/news/20101110/Data-from-AVEOs-tivozanib-FOLFOX6-combination-Phase-1b-trial-presented-at-22nd-EORTC-NCI-AACR.aspx)